Stock Track | Privia Health Stock Soars 5.12% Pre-Market on Strong Q3 Results and Raised Guidance

Stock Track11-06

Shares of Privia Health Group, Inc. (PRVA) surged 5.12% in pre-market trading on Thursday following the release of the company's impressive third-quarter financial results and raised full-year guidance. The healthcare technology and services provider reported strong performance across key metrics, beating analyst expectations on several fronts.

For the third quarter ended September 30, 2025, Privia Health reported revenue of $580.4 million, representing a 32.5% increase year-over-year. While this fell short of some analyst estimates, the company's adjusted EBITDA of $38.2 million significantly outperformed expectations, showing a 61.6% growth compared to the same period last year. Net income for the quarter reached $6.9 million, a substantial 94.1% increase from Q3 2024.

Investors were particularly encouraged by Privia Health's raised full-year 2025 guidance. The company now expects revenue in the range of $2.05 billion to $2.10 billion, up from previous estimates. Additionally, Privia Health reported strong growth in implemented providers (+13.1% year-over-year) and practice collections (+27.1% year-over-year), indicating robust expansion of its healthcare network. The company also announced plans to acquire an ACO business from Evolent Health, which is expected to further strengthen its position in value-based care arrangements. With a solid balance sheet showing $441.4 million in cash and no debt, Privia Health appears well-positioned for continued growth and strategic investments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment